Key result
Coronary microvascular dysfunction drives pathogenesis in obstructive and non-obstructive coronary syndromes and HFpEF.
Why the study?
Despite recent diagnostic advancements, coronary microvascular dysfunction is often under-appreciated in clinical practice, and understanding it may allow for the development of novel therapeutic targets.
Coronary microvascular dysfunction is an under-appreciated but prognostically significant condition across multiple cardiovascular diseases, requiring specific diagnostic evaluation and targeted therapeutic strategies.
The coronary microcirculation plays a cardinal role in regulating coronary blood flow to meet the changing metabolic demands of the myocardium. Coronary microvascular dysfunction (CMD) refers to structural and functional remodeling of the coronary microcirculation. CMD plays a role in the pathogenesis of obstructive and non-obstructive coronary syndromes as well as myocardial diseases, including heart failure with preserved ejection fraction (HFpEF). Despite recent diagnostic advancements, CMD is often under-appreciated in clinical practice, and may allow for the development of novel therapeutic targets. This review explores the diagnosis and pathogenic role of CMD across a range of cardiovascular diseases, its prognostic significance, and the current therapeutic landscape.
No takes yet. Share an insight, caveat, or question.
Rehan et al. (2023) conducted a review in Coronary microvascular dysfunction. Coronary microvascular dysfunction plays a pathogenic role in obstructive and non-obstructive coronary syndromes and HFpEF, highlighting the need for improved diagnosis and novel therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: